PF-06741086 Long-term Treatment in Severe Hemophilia
A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
SAO Paulo
-
Campinas, SAO Paulo, Brazil, 13083-878
- Centro de Hematologia e Hemoterapia de Campinas- Hemocentro de Campinas
-
-
-
-
Puente ALTO
-
Santiago, Puente ALTO, Chile, 8207257
- Hospital Dr. Sotero del Rio
-
-
-
-
-
Zagreb, Croatia, 10000
- Klinicki bolnicki centar Zagreb
-
-
-
-
-
Gdansk, Poland, 80-214
- Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne
-
-
-
-
Eastern CAPE
-
Port Elizabeth, Eastern CAPE, South Africa, 6001
- Phoenix Pharma (Pty) Ltd
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Zurich, Switzerland, 8091
- Universitätsspital Zürich
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- UC Denver Hemophilia and Thrombosis Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe hemophilia A or B (Factor VIII or Factor IX activity ≤ 1%)
- Subjects enrolled as Factor VIII or Factor IX inhibitor patients must have a positive inhibitor test result (above the upper limit of normal) at the local laboratory and must receive a bypass agent as primary treatment for bleeding episodes.
- Episodic (on-demand) treatment regimen prior to screening
- At least 6 acute bleeding episodes during the 6-month period prior to screening
Exclusion Criteria:
- Known coronary artery, thrombotic, or ischemic disease
- Concomitant treatment with activated prothrombin complex concentrate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: PF-06741086 (Cohort 1)
|
PF-06741086 subcutaneous injection
|
|
EXPERIMENTAL: PF-06741086 (Cohort 2)
|
PF-06741086 subcutaneous injection
|
|
EXPERIMENTAL: PF-06741086 (Cohort 3)
|
PF-06741086 subcutaneous injection
|
|
EXPERIMENTAL: PF-06741086 (Cohort 4)
|
PF-06741086 subcutaneous injection
|
|
EXPERIMENTAL: PF-06741086 (Cohort 5)
|
PF-06741086 subcutaneous injection
|
|
EXPERIMENTAL: PF-06741086 (Cohort 6)
|
PF-06741086 subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related)
Time Frame: Day 1 up to Day 393
|
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment.
A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect.
AEs included both SAEs and non-serious AEs.
TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment.
Treatment-related TEAEs were determined by the investigator.
Grades 3 AEs were severe and undesirable adverse events.
Grades 4 AEs were life threatening or disabling adverse events.
|
Day 1 up to Day 393
|
|
Number of Participants With Abnormal Laboratory Findings Without Regard to Baseline Abnormality (Including Hematology, Serum Chemistry, and Urinalysis)
Time Frame: Hematology and serum chemistry: Baseline, Days 1, 29, 57, 85, 169, 253, and 365 visits. Urinalysis: Baseline, Days 1, 85, 169, 253, and 365 visits.
|
Following parameters were analyzed for laboratory examination: hematology, clinical chemistry, and urinalysis.
The hematology parameters and pre-defined criteria included: neutrophils (10^3/millimeter[mm]^3) <0.8*lower limit of normal (LLN), and basophils (10^3/mm^3) >1.2*upper limit of normal (ULN).
The clinical chemistry parameter and pre-defined criteria included: bilirubin (milligrams [mg]/decilitre [dL]) >1.5 ULN, aspartate aminotransferase (units [U]/liter [L]) >3.0 ULN, glucose (mg/dL) >1.5*ULN.
The urinalysis parameter and pre-defined criteria included: urine glucose ≥1, ketones (scalar) ≥1, urine protein ≥1, urine hemoglobin (scalar) ≥1, and hyaline casts per low power field (/LPF).
Participants met criteria at any time point were included.
|
Hematology and serum chemistry: Baseline, Days 1, 29, 57, 85, 169, 253, and 365 visits. Urinalysis: Baseline, Days 1, 85, 169, 253, and 365 visits.
|
|
Number of Participants With Changes From Baseline in Vital Signs Measurements Meeting the Pre-Defined Categorical Summarization Criteria
Time Frame: Baseline, Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365 and 393 visits.
|
Following parameters were analyzed for vital sign examination: blood pressure (BP), pulse rate (PR), temperature, respiration rate.
Categorical vital signs: Temperature >38.5 degree(s) Celsius (℃), Supine PR: <40 or >120 beats per minute (BPM), Systolic BP: <90 mm Hg, >=30 mm Hg change from baseline, Diastolic BP: <50 mm Hg, >=20 mm Hg change from baseline.
|
Baseline, Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365 and 393 visits.
|
|
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters Meeting the Pre-defined Categorical Summarization Criteria
Time Frame: Baseline, Days 1 and 29 visits
|
Baseline was defined as the average of triplicate ECG measurements collected prior to dosing on Day 1 in B7841003.
Criteria for potentially clinically important changes in ECG were defined as: PR interval value >=300 millisecond (msec); PR interval baseline >200 msec and change >=25%; PR interval baseline <=200 msec and change >=50%; QRS complex value >=140 msec and change >=50%; QTcF value >=450 msec and change >=30 msec.
Only the number of participants meeting pre-defined criteria was reported below.
|
Baseline, Days 1 and 29 visits
|
|
Number of Participants With Abnormalities in Physical Examination Findings
Time Frame: Day 1 to Day 393
|
Physical examinations were conducted by a physician, trained physician's assistant, or nurse practitioner as acceptable according to local regulation.
A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
The limited or abbreviated physical examination was focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.
For measuring weight, a scale with appropriate range and resolution was used and must have been placed on a stable, flat surface.
Participants removed shoes, bulky layers of clothing, and jackets so that only light clothing remains.
They also removed the contents of their pockets and remain still during measurement of weight.
|
Day 1 to Day 393
|
|
Number of Participants With Injection Site Reactions
Time Frame: Day 1 to Day 365, and Day 393 visit.
|
Injection site reactions included but were not limited to: erythema, induration, ecchymosis, pain and pruritus.
Grade of severity was defined as follows: Mild: Transient or mild discomfort (< 48 hours); no medical intervention/therapy required.
Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required.
Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.
|
Day 1 to Day 365, and Day 393 visit.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Annualized Bleeding Rate (ABR)
Time Frame: Day 1 to Day 365, and Day 393 visit. Pre-Treatment summarized the data up to 6 months prior to participation in B7841003 for de novo participants and up to 6 months prior to participation in B7841002 for roll over participants.
|
The ABR was calculated as ([number of bleeding events × 365.25] / observed treatment period in days)
|
Day 1 to Day 365, and Day 393 visit. Pre-Treatment summarized the data up to 6 months prior to participation in B7841003 for de novo participants and up to 6 months prior to participation in B7841002 for roll over participants.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B7841003
- 2017-001255-31 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.